Yale researchers develop mRNA-based lyme disease vaccine

Yale researchers have developed an mRNA vaccine that targets the antigens found in tick saliva in order to alert individuals to tick bites as well as prevent the tick from feeding correctly, thereby reducing its ability to transmit pathogens.

Cate RoserYale researchers have developed an mRNA vaccine against lyme disease that triggers an immune response at the site of a tick bite and provides partial protection against the disease-causing bacteria.

In a paper published on Nov. 17 in the Science Translational Medicine journal, scientists studied specific ticks called “Ixodes scapulari” that carry a lyme-disease-causing bacteria called “Borrelia burgdorferi.” According to Gunjan Arora, one of the co-first authors of the paper and an associate research scientist at the Yale School of Medicine, lyme disease is the fastest-growing vector-borne illness in the United States, with close to half a million people affected every year. Currently, there are no commercially available vaccines for lyme disease. This novel vaccine is unique in that it targets the vector of transmission, the tick, rather than the actual pathogen itself. (See link for article)


A few important points:

  • The article erroneously states it takes around 24 hours for transmission, when it can happen much more quickly.
  • They state they don’t expect pathogen resistance from it.
  • They state ticks don’t feed well on “vaccinated” animals and usually fall off quickly and will give the host opportunity to remove ticks before transmission but provides partial protection if the tick isn’t removed.
  • Preliminary findings showed that no “vaccinated” guinea pigs bitten by ticks tested positive for borrelia and that they developed EM rashes which they state is a sign of acquired tick resistance.  I completely disagree.  EM rash is diagnostic of Lyme.  You have the rash – YOU ARE INFECTED.
  • Similarly to the COVID-19 mRNA “vaccines”, it uses mRNA encapsulated in lipid nanoparticles, but unlike the COVID-19 vaccines that target a single antigen — the spike protein on SARS-CoV-2 — the lyme disease vaccine targets 19 antigens — the different salivary proteins in tick bites.
  • The “vaccine” still needs human trials in order to determine its effectiveness.
  • This shot doesn’t take into account Lyme disease for many is a chronic issue caused by complex issues, one of which is a persistent infection.  There are also immune issues. The mRNA “vaccines” are designed so that the immune system recognizes these proteins, sees them as an antigen and triggers a strong immune response at the site of the bite. The problem here is Lyme/MSIDS patients have very whacked-out immune systems. Nearly anything can serve as a trigger for them from light, to sound, to touch, to smells.  Injecting these people with foreign proteins would be a death-toll for them. I predict the same catastrophic reactions as the other “Lyme vaccines.”
  • This shot doesn’t take into account that Lyme rarely comes alone and that most patients are infected with numerous pathogens, with a net result of complex, complicated cases.
  • These researchers, drinking the Kool-aid of “the powers that be,” have a faulty premise for their entire paradigm.  Run away fast from this injection.

I’m not holding my breath.  This reminds me of Willy Burgdorfer’s creation of a Rickettsial vaccine where he essentially injected guinea pigs and rabbits with live organisms, placed ticks on them to feed for a couple days, doused the ticks with formalin, and then ground them up and used the filtered, diluted “tick juice” as a vaccine.  No thanks.

Notice that the race is always for a “vaccine”, never an effective treatment.  There’s no money in that.

For more:

%d bloggers like this: